Srpt stock price target

8 Mar 2020 Top trades and best-performing strategies with Sarepta Therapeutics, maintained an Overweight rating but raised its price target from $160 to 

Messer kept his buy rating on SRPT stock, and raised his price target to 182 from 170. Sarepta has said Vyondys 53 will be priced on parity with Exondys 51, its predecessor, Messer said. The price Sarepta Therapeutics (NASDAQ:SRPT) Receives “Buy” Rating ... Sarepta Therapeutics (NASDAQ:SRPT) ‘s stock had its “buy” rating restated by research analysts at Nomura in a research report issued to clients and investors on Tuesday, AnalystRatings.com reports. They currently have a $230.00 target price on the biotechnology company’s stock. Nomura’s price objective points to a potential upside of 92.36% from the company’s current price. Sarepta Therapeutics, Inc. (SRPT) Stock Analysis & News ... Get breaking news and analysis on Sarepta Therapeutics, Inc. (SRPT) stock, price quote and chart, trading and investing tools. Sarepta Stock Is Soaring on $1 Billion Deal With Roche ... Dec 23, 2019 · On Monday morning, Sarepta Therapeutics announced that Roche would pay $1.2 billion up front for the rights to sell Sarepta’s experimental gene …

Stockopedia rates Sarepta Therapeutics Inc as a Adventurous Momentum Trap . 15 brokers rate StockRank™ · StockReport™ Price Target: ( below Price).

Stock Target Advisor runs millions of automatic calculations on over 75,000 stocks in American, Asian and European Exchanges and compares it with market analyst stock ratings and target stock prices to help you make smart investment decisions and build robust investment portfolios. Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 8.7% ... Sarepta Therapeutics Inc (NASDAQ:SRPT) fell 8.7% on Monday following insider selling activity. The company traded as low as $105.89 and last traded at $106.87, 946,677 shares changed hands during mid-day trading. An increase of 9% from the average session volume of 865,163 shares. The stock had previously closed at $117.10. Specifically, EVP Alexander Cumbo sold […] Sarepta Therapeutics Earnings Release Date - SRPT ... That means we are expecting the stock SRPT to move 7%. If we sell Puts at strike price close to 14%, the stock is less likely to reach the strike price. As a result, Options for SRPT could expire worthless. You get to keep the whole premium. This is a short term Option strategy to take advantage of High Volatility from Earning Announcement of SRPT. JPMorgan Chase & Co. Cuts Sarepta Therapeutics (NASDAQ ... Sarepta Therapeutics (NASDAQ:SRPT) had its price target cut by JPMorgan Chase & Co. from $172.00 to $160.00 in a research note published on Friday, BenzingaRatingsTable reports. They currently have an overweight rating on the biotechnology company’s stock. Other analysts have also issued reports about the …

Apr 02, 2020 · Real time Sarepta Therapeutics (SRPT) stock price quote, stock graph, news & analysis. Real time Sarepta Therapeutics (SRPT) stock price quote, stock graph, news & analysis.

Find the latest analyst research for Sarepta Therapeutics, Inc. Common Stock ( DE) (SRPT) at Nasdaq.com. Analyst price targets provided by TipRanks. Sarepta Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. SRPT updated stock price target summary. View SRPT revenue estimates and earnings estimates, as well as analyst recommendations. Bulletin U.S. stocks slump early Monday amid fear of escalating Iran conflict » Average Recommendation: Buy, Average Target Price : 196.50. SRPT | Complete Sarepta Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. The average analyst SRPT price target for one year from now, presented by ETF difference to the ETF as far as deciding whether to continue to hold the stock. View today's stock price, news and analysis for Sarepta Therapeutics Inc. (SRPT) . Barron's also provides information on historical stock ratings, target prices,  GO IN-DEPTH ON Sarepta Therapeutics STOCK. Snapshot · LIVE QUOTE · Price · News · Financials · Analysts · Dividend · Calendar · Profile · Chart-Tool.

20 Dec 2019 Baird analyst Brian Skorney raised the price target on Sarepta Therapeutics ( NASDAQ: SRPT) to $192.00 (from $181.00) while maintaining an 

View live SAREPTA THERAPEUTICS INC chart to track its stock's price action. Find market predictions, SRPT financials and market news. View live SAREPTA THERAPEUTICS INC chart to track its stock's price action. Find market predictions, SRPT financials and market news. Entry level $146 = Target price $158 = Stop loss $142 We have been Sarepta Therapeutics, Inc. - SRPT - Stock Price Today - Zacks View Sarepta Therapeutics, Inc. SRPT investment & stock information. Get the latest Sarepta Therapeutics, Inc. SRPT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. SRPT Stock Quote - Sarepta Therapeutics, Inc. Common Stock ... Stock quote for Sarepta Therapeutics, Inc. Common Stock (DE) Common Stock (SRPT) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq. SRPT Stock Rockets After Biotech Company's New DMD Drug ... Messer kept his buy rating on SRPT stock, and raised his price target to 182 from 170. Sarepta has said Vyondys 53 will be priced on parity with Exondys 51, its predecessor, Messer said. The price

Mar 27, 2020 · Sarepta Therapeutics, Inc. Common Stock (DE) (SRPT) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on February 28, 2020 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material

8 Mar 2020 Top trades and best-performing strategies with Sarepta Therapeutics, maintained an Overweight rating but raised its price target from $160 to  View Sarepta Therapeutics, Inc.'s fair value, stock price, financial statements, Sarepta Therapeutics, Inc. Analysts Are Cutting Their Estimates: Here's